<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ</journal-id><journal-id journal-id-type="publisher-id">bmj</journal-id><journal-title>BMJ : British Medical Journal</journal-title><issn pub-type="ppub">0959-8138</issn><issn pub-type="epub">1468-5833</issn><publisher><publisher-name>BMJ Publishing Group Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19218323</article-id><article-id pub-id-type="pmc">2645848</article-id><article-id pub-id-type="publisher-id">gekj586503</article-id><article-id pub-id-type="doi">10.1136/bmj.b138</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Comparison of different strategies in prenatal screening for Down&#x02019;s syndrome: cost effectiveness analysis of computer simulation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Gekas</surname><given-names>Jean</given-names></name><role>chief of prenatal diagnosis unit, consultant in medical genetic, and professor</role><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Gagn&#x000e9;</surname><given-names>Genevi&#x000e8;ve</given-names></name><role>research assistant</role><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Bujold</surname><given-names>Emmanuel</given-names></name><role>consultant obstetrician and professor</role><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Douillard</surname><given-names>Daniel</given-names></name><role>research assistant</role><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Forest</surname><given-names>Jean-Claude</given-names></name><role>chief of medical biochemistry service, director of CHUQ medical research centre, and professor</role><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Reinharz</surname><given-names>Daniel</given-names></name><role>professor</role><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Rousseau</surname><given-names>Fran&#x000e7;ois</given-names></name><role>professor</role><xref ref-type="aff" rid="aff4">4</xref></contrib><aff id="aff1"><label>1</label>Centre de recherche du CHUQ, Service de G&#x000e9;n&#x000e9;tique M&#x000e9;dicale, Unit&#x000e9; de Diagnostic Pr&#x000e9;natal, Facult&#x000e9; de M&#x000e9;decine, Universit&#x000e9; Laval, Qu&#x000e9;bec city, Qu&#x000e9;bec, Canada</aff><aff id="aff2"><label>2</label>Centre de recherche du CHUQ, D&#x000e9;partement de m&#x000e9;decine sociale et pr&#x000e9;ventive, Facult&#x000e9; de M&#x000e9;decine, Universit&#x000e9; Laval, Cit&#x000e9; universitaire, Qu&#x000e9;bec city</aff><aff id="aff3"><label>3</label>Centre de recherche du CHUQ, Unit&#x000e9; de Diagnostic Pr&#x000e9;natal, D&#x000e9;partement d&#x02019;Obst&#x000e9;trique-Gyn&#x000e9;cologie, Facult&#x000e9; de M&#x000e9;decine, Universit&#x000e9; Laval, Qu&#x000e9;bec city</aff><aff id="aff4"><label>4</label>Centre de recherche du CHUQ, D&#x000e9;partement de biologie m&#x000e9;dicale, Facult&#x000e9; de M&#x000e9;decine, Universit&#x000e9; Laval, The CanG&#x000e8;neTest research consortium on genetic laboratory services, Qu&#x000e9;bec city</aff></contrib-group><author-notes><corresp>Correspondence to: J Gekas, Centre Hospitalier de l&#x02019;Universit&#x000e9; Laval (CHUL), 2705, boul. Laurier, bureau RC-9300, Sainte-Foy, Qu&#x000e9;bec city, G1V 4G2, Qu&#x000e9;bec, Canada <email>jean.gekas@mail.chuq.qc.ca</email></corresp></author-notes><!--For BMJ, both ppub and collection dates generated for PMC processing starting July 2008 beck--><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>13</day><month>2</month><year>2009</year></pub-date><volume>338</volume><elocation-id>b138</elocation-id><history><date date-type="accepted"><day>12</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>&#x000a9; Gekas et al 2009</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Gekas et al</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><self-uri xlink:title="pdf" xlink:href="bmj.b138.pdf"/><abstract><p><bold>Objectives</bold> To assess and compare the cost effectiveness of three different strategies for prenatal screening for Down&#x02019;s syndrome (integrated test, sequential screening, and contingent screenings) and to determine the most useful cut-off values for risk.</p><p><bold>Design</bold> Computer simulations to study integrated, sequential, and contingent screening strategies with various cut-offs leading to 19 potential screening algorithms. </p><p><bold>Data sources</bold> The computer simulation was populated with data from the Serum Urine and Ultrasound Screening Study (SURUSS), real unit costs for healthcare interventions, and a population of 110&#x02009;948 pregnancies from the province of Qu&#x000e9;bec for the year 2001.</p><p><bold>Main outcome measures</bold> Cost effectiveness ratios, incremental cost effectiveness ratios, and screening options&#x02019; outcomes.</p><p><bold>Results</bold> The contingent screening strategy dominated all other screening options: it had the best cost effectiveness ratio ($C26&#x02009;833 per case of Down&#x02019;s syndrome) with fewer procedure related euploid miscarriages and unnecessary terminations (respectively, 6 and 16 per 100&#x02009;000 pregnancies). It also outperformed serum screening at the second trimester. In terms of the incremental cost effectiveness ratio, contingent screening was still dominant: compared with screening based on maternal age alone, the savings were $C30&#x02009;963 per additional birth with Down&#x02019;s syndrome averted. Contingent screening was the only screening strategy that offered early reassurance to the majority of women (77.81%) in first trimester and minimised costs by limiting retesting during the second trimester (21.05%). For the contingent and sequential screening strategies, the choice of cut-off value for risk in the first trimester test significantly affected the cost effectiveness ratios (respectively, from $C26&#x02009;833 to $C37&#x02009;260 and from $C35&#x02009;215 to $C45&#x02009;314 per case of Down&#x02019;s syndrome), the number of procedure related euploid miscarriages (from 6 to 46 and from 6 to 45 per 100&#x02009;000 pregnancies), and the number of unnecessary terminations (from 16 to 26 and from 16 to 25 per 100&#x02009;000 pregnancies).</p><p><bold>Conclusions</bold> Contingent screening, with a first trimester cut-off value for high risk of 1 in 9, is the preferred option for prenatal screening of women for pregnancies affected by Down&#x02019;s syndrome. </p></abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>In the past 10-15 years, major advances have been made in prenatal screening for Down&#x02019;s syndrome,<xref ref-type="bibr" rid="ref1">1</xref> <xref ref-type="bibr" rid="ref2">2</xref> the foremost known genetic cause of mental retardation.<xref ref-type="bibr" rid="ref3">3</xref> It has been suggested that maternal age alone as a screening strategy should be abandoned,<xref ref-type="bibr" rid="ref4">4</xref> but there is still no consensus on the most cost effective alternative, and thus no national strategy exists in the United States or Canada.<xref ref-type="bibr" rid="ref5">5</xref> <xref ref-type="bibr" rid="ref6">6</xref></p><p>New strategies that allow a relatively high detection rate combine analyses from first and second trimesters of pregnancy.<xref ref-type="bibr" rid="ref7">7</xref> <xref ref-type="bibr" rid="ref8">8</xref> Different approaches have been proposed<xref ref-type="bibr" rid="ref6">6</xref> <xref ref-type="bibr" rid="ref7">7</xref> <xref ref-type="bibr" rid="ref9">9</xref> such as </p><list list-type="bullet"><list-item><p>The integrated test, in which the results from first trimester screening tests are not analysed until the results from second trimester tests are evaluated, when both sets are assessed together<xref ref-type="bibr" rid="ref1">1</xref></p></list-item><list-item><p>Sequential screening, in which first trimester screening results determine whether second trimester testing is indicated: women with a positive first trimester result are offered invasive testing (chorionic villous sampling), whereas those with a negative result are offered another serum test<xref ref-type="bibr" rid="ref10">10</xref> </p></list-item><list-item><p>Contingent screening, in which the first trimester screening results are used to categorise women as high, intermediate, or low risk.<xref ref-type="bibr" rid="ref11">11</xref> High risk women are offered early diagnosis (chorionic villous sampling), low risk women are reassured and do not undergo second trimester testing, and intermediate risk women are offered second trimester testing. The cut-off values between the risk categories vary depending on how the groups are defined.</p></list-item></list><p>Published evaluations of screening programmes for Down&#x02019;s syndrome have primarily focused on the detection rates of the different strategies used.<xref ref-type="bibr" rid="ref6">6</xref> Although the detection rate is important for individuals, the cost effectiveness ratio and similar end points of screening strategies are needed for the development of optimal public health strategies.<xref ref-type="bibr" rid="ref6">6</xref> In that respect, only contradictory and limited data exist on the three above methods of combining first and second trimester tests.<xref ref-type="bibr" rid="ref6">6</xref> <xref ref-type="bibr" rid="ref9">9</xref> Using a decision analysis model based on data from the First and Second Trimester Evaluation of Risk (FASTER) trial,<xref ref-type="bibr" rid="ref12">12</xref> Ball et al reported that contingent screening dominated (lower costs with better outcomes) the integrated test.<xref ref-type="bibr" rid="ref6">6</xref> In contrast, Wald et al&#x02014;summarising the modelling of integrated, sequential, and contingent screening strategies from data derived from the Serum Urine and Ultrasound Screening Study (SURUSS)<xref ref-type="bibr" rid="ref13">13</xref>&#x02014;concluded that integrated screening had the best screening performance.<xref ref-type="bibr" rid="ref9">9</xref> However, recent reports underline the insufficiency of data on these three screening strategies.<xref ref-type="bibr" rid="ref5">5</xref> <xref ref-type="bibr" rid="ref9">9</xref> <xref ref-type="bibr" rid="ref14">14</xref> For sequential and contingent testing, there is no consensus on cut-off levels, resulting in variations in performance measured.<xref ref-type="bibr" rid="ref8">8</xref> A workshop of experts convened by the National Institutes of Health concluded that the contingent screening strategy needed further study before its widespread implementation could be recommended.<xref ref-type="bibr" rid="ref8">8</xref></p><p>Given the countless screening strategies available,<xref ref-type="bibr" rid="ref7">7</xref> <xref ref-type="bibr" rid="ref15">15</xref> regional differences in local resources,<xref ref-type="bibr" rid="ref5">5</xref> <xref ref-type="bibr" rid="ref16">16</xref> and the costs of prospective clinical studies,<xref ref-type="bibr" rid="ref17">17</xref> no empirical study can be foreseen that would compare all options available for the three approaches to combining first and second trimester analyses. There are indeed too many possible combinations of tests, sequences, cut-off values, and schedules to be handled in a single study. Only computer simulations can compare all the options to identify the most cost effective.<xref ref-type="bibr" rid="ref6">6</xref> <xref ref-type="bibr" rid="ref9">9</xref> <xref ref-type="bibr" rid="ref17">17</xref> <xref ref-type="bibr" rid="ref18">18</xref> <xref ref-type="bibr" rid="ref19">19</xref></p><p>In the current analysis, we performed computer simulations to compare 19 different screening options based on the three screening approaches (integrated test and sequential and contingent screenings) with various cut-off levels and using real data from the SURUSS trials.<xref ref-type="bibr" rid="ref9">9</xref> <xref ref-type="bibr" rid="ref13">13</xref> Our aims were to</p><list list-type="bullet"><list-item><p>Analyse the cost effectiveness ratio of the different screening options from a public health perspective</p></list-item><list-item><p>Compare their performance estimates for an overall 90% detection rate by evaluating seven other relevant end points that cover the main outcomes in prenatal screening for Down&#x02019;s syndrome<xref ref-type="bibr" rid="ref9">9</xref> <xref ref-type="bibr" rid="ref17">17</xref>:</p><list list-type="simple"><list-item><p>1) False positive rate that defines the number of scheduled amniocentesis procedures</p></list-item><list-item><p>2) Number of procedure related miscarriages of normal (euploid) fetuses </p></list-item><list-item><p>3) Number of live births with Down&#x02019;s syndrome </p></list-item><list-item><p>4) Number of unnecessary terminations</p></list-item><list-item><p>5) Proportion of pregnancies affected by Down&#x02019;s syndrome that were screened by a first trimester test</p></list-item><list-item><p>6) Proportion of patients reassured early in gestation by first trimester testing</p></list-item><list-item><p>7) Proportion of continuing pregnancies that proceed to a second trimester test </p></list-item></list></list-item><list-item><p>Compare the effects of eight different first trimester cut-off values in contingent and sequential screening strategies to determine the optimal value.</p></list-item></list></sec><sec sec-type="materials|methods"><title>Material and methods</title><sec><title>Screening strategies and tests</title><p>The screening strategies considered were the integrated test, sequential screening, and contingent screening compared with maternal age alone (&#x02265;35 years), which has been the standard since antenatal diagnosis guidelines for invasive testing were established in the US in the late 1970s,<xref ref-type="bibr" rid="ref20">20</xref> and the triple test, which has been widely available in Europe and Canada since 1991.<xref ref-type="bibr" rid="ref8">8</xref> <xref ref-type="bibr" rid="ref16">16</xref> <xref ref-type="bibr" rid="ref21">21</xref> The box gives further details of the screening strategies and the tests used.</p><boxed-text position="float" content-type="style2"><sec sec-type="methods"><title>Definitions of screening procedures </title><sec><title>Integrated test</title><p>Measurements performed at different times of pregnancy are integrated into a single test result. Unless otherwise qualified, it refers to the integration of nuchal translucency measurement (by ultrasound scan of the width of an area of translucency at the back of the fetal neck) and measurement of pregnancy associated plasma protein A (PAPP-A) in the first trimester with the quadruple test markers in the second trimester (measurement of maternal serum concentrations of &#x003b1; fetoprotein, unconjugated oestriol, free or total &#x003b2; human chorionic gonadotrophin, and inhibin A) together with maternal age.</p></sec><sec><title>Sequential screening</title><p>First trimester tests are performed (nuchal translucency measurement and PAPP-A) and interpreted immediately. If the result is positive, the mother is offered a diagnostic test (chorionic villous sampling), but if it is not positive, second trimester serum markers (quadruple test markers) are measured and the results combined with the first trimester results to form an integrated test. </p></sec><sec><title>Contingent screening</title><p>First trimester tests (nuchal translucency measurement and PAPP-A) are used to categorise pregnant women as high, low, or intermediate risk. High risk women (positive result) are immediately offered a diagnostic test (chorionic villous sampling), low risk women (negative test result) receive no further screening, and intermediate risk women (lower risk positive result) undergo second trimester screening (quadruple test markers) for an integrated test to be done.</p></sec><sec><title>Triple test</title><p>Second trimester test based on the measurement of maternal serum &#x003b1; fetoprotein, unconjugated oestriol, and free or total &#x003b2; human chorionic gonadotrophin, together with maternal age.</p></sec></sec></boxed-text><p>Sequential and contingent screening strategies consist of a sequence of tests with many possible cut-off values for the risk of the fetus having Down&#x02019;s syndrome, but screening performance has been reported for only eight different cut-off points for first trimester tests (1 in 6, 1 in 9, 1 in 30, 1 in 58, 1 in 114, 1 in 175, 1 in 237, and 1 in 307).<xref ref-type="bibr" rid="ref9">9</xref> We compared 19 screening algorithms comprised possible screening scenarios resulting from the three screening strategies (integrated test and sequential and contingent screening), different cut-off values for contingent and sequential screenings, the triple test, and maternal age alone. For contingent screening, we also used a lower risk cut-off of 1 in 2000.</p></sec><sec><title>Diagnostic tests</title><p>The diagnostic procedures included in our simulation were conditional on the stage of pregnancy in accordance with best practice in prenatal care. Thus, amniocentesis was used for prenatal diagnosis only after second trimester screenings results, whereas women with a positive result at the first trimester screening were considered for transabdominal chorionic villous sampling for caryotyping. Timing of procedure-related euploid miscarriages is dependent on the test undergone. Our computer model also accounted for the performance characteristics of the diagnostic tests (amniocentesis and chorionic villous sampling).</p></sec><sec><title>Decision model</title><p>We developed a computer program in C11 language that simulates all 19 screening scenarios. The program was devised to </p><list list-type="bullet"><list-item><p>Generate a virtual population with characteristics related to the prevalence and clinical course of pregnancies affected by Down&#x02019;s syndrome and unaffected pregnancies, as well as maternal age distribution</p></list-item><list-item><p>Construct the various screening algorithms for the screening and diagnosis options for Down&#x02019;s syndrome</p></list-item><list-item><p>Simulate screening of this virtual population with each algorithm and measure pregnancy outcomes</p></list-item><list-item><p>Establish the direct healthcare costs of each screening option using costs of procedures and of complications provided by the Ministry of Health. </p></list-item></list><p>Figure 1<xref ref-type="fig" rid="fig1"/> shows a simplified version of the decision model. The model includes several possible outcomes of screening and diagnostic testing decisions, including birth of a baby with no chromosomal disorder, birth of a baby with Down&#x02019;s syndrome, miscarriage, elective abortion after positive test results, and whether a pregnancy loss occurs after a diagnostic test.</p><fig id="fig1" position="float"><caption><p><bold>Fig 1</bold>&#x02002;Simplified version of the decision model for screening options (panel A) and diagnosis procedure (panel B) used in computer simulation of prenatal screening strategies for Down&#x02019;s syndrome. Not shown, but included in the real model, is the possibility that miscarriage occurs before testing or after test results are known</p></caption><graphic xlink:href="gekj586503.f1"/></fig></sec><sec><title>Data used in analysis</title><p>Table 1<xref ref-type="table" rid="tbl1"/> lists all the input variables and their data sources. Table 2<xref ref-type="table" rid="tbl2"/> shows the demographic characteristics of the virtual population used in our computer simulation and the most critical assumptions. Our virtual population of 110&#x02009;948 pregnancies corresponded to all pregnancies in Qu&#x000e9;bec province in year 2001<xref ref-type="bibr" rid="ref22">22</xref> <xref ref-type="bibr" rid="ref23">23</xref> with the same maternal age distribution. This population was of mixed origins, mainly white, and table 2 contains details of maternal ages.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>&#x02002;Input variables used in computer simulation of 19 different screening options in prenatal screening for Down&#x02019;s syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="left" valign="top">Input variables</th><th colspan="1" rowspan="1" align="center" valign="top">Value</th><th colspan="1" rowspan="1" align="center" valign="top">Data sources</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="bottom" content-type="TableSubHead"><bold>Costs of procedures</bold></td><td colspan="1" rowspan="1" align="center" valign="bottom" content-type="TableSubHead"><bold>Costs ($C)*</bold></td><td colspan="1" rowspan="1" align="center" valign="bottom" content-type="TableSubHead"><bold/></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Integrated test</td><td colspan="1" rowspan="1" align="center" valign="top">65.00</td><td colspan="1" rowspan="4" align="center" valign="middle">MSSS (2005),<sup>30</sup> (2007),<sup>31</sup> RAMQ (2007)<sup>33</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Sequential screening</td><td colspan="1" rowspan="1" align="center" valign="top">105.00</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Contingent screening</td><td colspan="1" rowspan="1" align="center" valign="top">55.00</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Triple test</td><td colspan="1" rowspan="1" align="center" valign="top">15.00</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Consulting with a genetic counsellor</td><td colspan="1" rowspan="1" align="center" valign="top">73.90</td><td colspan="1" rowspan="1" align="center" valign="top">RAMQ (2007)<sup>33</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Chorionic villous sampling</td><td colspan="1" rowspan="1" align="center" valign="top">876.00</td><td colspan="1" rowspan="2" align="center" valign="middle">MSSS (2005),<sup>30</sup> (2007),<sup>31</sup> RAMQ (2005),<sup>33</sup> (2007)<sup>33</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Amniocentesis</td><td colspan="1" rowspan="1" align="center" valign="top">500.00</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Termination of pregnancy</td><td colspan="1" rowspan="1" align="center" valign="top">1357.33</td><td colspan="1" rowspan="1" align="center" valign="top">MSSS (2003)<sup>29</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="bottom" content-type="TableSubHead"><bold>Screening tests with 90% detection rate</bold></td><td colspan="1" rowspan="1" align="center" valign="bottom" content-type="TableSubHead"><bold>False positive rate (%)</bold></td><td colspan="1" rowspan="1" align="center" valign="bottom" content-type="TableSubHead"><bold/></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Integrated test (1/245 cut-off value)</td><td colspan="1" rowspan="1" align="center" valign="top">2.60</td><td colspan="1" rowspan="1" align="center" valign="top">Wald et al (2003)<sup>13</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Sequential screening, cut-off values for first trimester test:</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="9" align="center" valign="middle">Wald et al (2006)<sup>9</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/6</td><td colspan="1" rowspan="1" align="center" valign="top">2.11</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/9</td><td colspan="1" rowspan="1" align="center" valign="top">2.12</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/30</td><td colspan="1" rowspan="1" align="center" valign="top">2.25</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/58</td><td colspan="1" rowspan="1" align="center" valign="top">2.46</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/114</td><td colspan="1" rowspan="1" align="center" valign="top">2.97</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/175</td><td colspan="1" rowspan="1" align="center" valign="top">3.65</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/237</td><td colspan="1" rowspan="1" align="center" valign="top">4.42</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/307</td><td colspan="1" rowspan="1" align="center" valign="top">5.23</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Contingent screening, cut-off values for first trimester test:</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="9" align="center" valign="middle">Wald et al (2006)<sup>9</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/6</td><td colspan="1" rowspan="1" align="center" valign="top">2.29</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/9</td><td colspan="1" rowspan="1" align="center" valign="top">2.29</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/30</td><td colspan="1" rowspan="1" align="center" valign="top">2.42</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/58</td><td colspan="1" rowspan="1" align="center" valign="top">2.62</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/114</td><td colspan="1" rowspan="1" align="center" valign="top">3.11</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/175</td><td colspan="1" rowspan="1" align="center" valign="top">3.74</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/237</td><td colspan="1" rowspan="1" align="center" valign="top">4.47</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/307</td><td colspan="1" rowspan="1" align="center" valign="top">5.27</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Triple test (1/690 cut-off value)</td><td colspan="1" rowspan="1" align="center" valign="top">14.70</td><td colspan="1" rowspan="1" align="center" valign="top">Wald et al (2003)<sup>13</sup></td></tr></tbody></table><table-wrap-foot><p>*Canadian dollars ($C), exchange rate in 2007: $C1.0748=$US1.00.</p></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>&#x02002;Demographic characteristics of the population and the most critical assumptions used in computer simulation of 19 different screening options in prenatal screening for Down&#x02019;s syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="left" valign="bottom">Characteristics</th><th colspan="1" rowspan="1" align="center" valign="bottom">Value</th><th colspan="1" rowspan="1" align="center" valign="bottom">Data sources</th></tr></thead><tbody><tr><td colspan="3" rowspan="1" align="left" valign="top" content-type="TableSubHead"><bold>Population simulated</bold></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Total No of pregnant women</td><td colspan="1" rowspan="1" align="center" valign="top">110 948</td><td colspan="1" rowspan="1" align="center" valign="top">MSSS (2007)<sup>23</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">No of pregnancies affected by Down&#x02019;s syndrome:</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="5" align="center" valign="middle">AETMIS (2003),<sup>22</sup> Snijders (1999),<sup>27</sup> Morris et al (1999)<sup>55</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;At first trimester</td><td colspan="1" rowspan="1" align="center" valign="top">290</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;At second trimester </td><td colspan="1" rowspan="1" align="center" valign="top">190</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;At third trimester </td><td colspan="1" rowspan="1" align="center" valign="top">140</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;At birth </td><td colspan="1" rowspan="1" align="center" valign="top">131</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">No of women by age (years):</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="11" align="center" valign="middle">MSSS (2007)<sup>23</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x0003c;20</td><td colspan="1" rowspan="1" align="center" valign="top">9 008</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;20-24</td><td colspan="1" rowspan="1" align="center" valign="top">24 987</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;25-29</td><td colspan="1" rowspan="1" align="center" valign="top">33 421</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;30-34</td><td colspan="1" rowspan="1" align="center" valign="top">27 320</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;35-39</td><td colspan="1" rowspan="1" align="center" valign="top">13 135</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;40-44</td><td colspan="1" rowspan="1" align="center" valign="top">2 925</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02265;45</td><td colspan="1" rowspan="1" align="center" valign="top">157</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x0003c;35 years old</td><td colspan="1" rowspan="1" align="center" valign="top">94 735</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;&#x02265;35 years old</td><td colspan="1" rowspan="1" align="center" valign="top">16 213</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Mean maternal age (years)</td><td colspan="1" rowspan="1" align="center" valign="top">27</td></tr><tr><td colspan="3" rowspan="1" align="left" valign="bottom" content-type="TableSubHead"><bold>Assumed probabilities (%)</bold></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Consent to participate in prenatal screening</td><td colspan="1" rowspan="1" align="center" valign="top">70.0</td><td colspan="1" rowspan="2" align="center" valign="middle">Forest et al (2004)<sup> 28</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Consent for amniocentesis or chorionic villous sampling with screening positive</td><td colspan="1" rowspan="1" align="center" valign="top">90.0</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Fetal loss from amniocentesis</td><td colspan="1" rowspan="1" align="center" valign="top">0.5</td><td colspan="1" rowspan="2" align="center" valign="top">AETMIS (2003),<sup>22</sup> Sundberg et al (1997),<sup>56</sup> CETS (1997)<sup>57</sup></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Fetal loss from chorionic villous sampling</td><td colspan="1" rowspan="1" align="center" valign="top">1.6</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Proportion who terminated pregnancy with fetal Down&#x02019;s syndrome</td><td colspan="1" rowspan="1" align="center" valign="top">90.0</td><td colspan="1" rowspan="1" align="center" valign="middle">Forest et al (2004)<sup>28</sup></td></tr></tbody></table></table-wrap></sec><sec><title>Probabilities</title><p><italic>Pregnancies affected by Down&#x02019;s syndrome and risk of miscarriage&#x02014;</italic>We estimated the risk of a pregnancy being affected by Down&#x02019;s syndrome by multiplying the specific odds by maternal age of having an affected live birth<xref ref-type="bibr" rid="ref24">24</xref> <xref ref-type="bibr" rid="ref25">25</xref> (corrected for the spontaneous miscarriage of fetuses with Down&#x02019;s syndrome<xref ref-type="bibr" rid="ref26">26</xref> <xref ref-type="bibr" rid="ref27">27</xref>) by the likelihood ratio (for a given set of marker values) obtained from the overlapping multivariate Gaussian distributions of marker levels in affected and unaffected pregnancies.<xref ref-type="bibr" rid="ref9">9</xref> If a woman chooses to undergo amniocentesis, she is at risk of a miscarriage before she has the test and either before or after the test results are given.</p><p><italic>Test performance&#x02014;</italic>We used the distribution of marker values in pregnancies affected by Down&#x02019;s syndrome and in unaffected pregnancies reported in the SURUSS trials to determine the parametric values (means, standard deviations, correlation coefficients, and truncation limits).<xref ref-type="bibr" rid="ref9">9</xref> <xref ref-type="bibr" rid="ref13">13</xref> We included rates of false positive and false negative test results in the calculations.</p><p><italic>Other probabilities&#x02014;</italic>Our simulation included the level of compliance previously estimated in the Qu&#x000e9;bec population<xref ref-type="bibr" rid="ref28">28</xref>&#x02014;that is, the proportion of women who consent to participate in prenatal screening for Down&#x02019;s syndrome and to a diagnostic test after a positive screening result. We also included the chance that a woman will choose elective abortion after a positive diagnostic test.<xref ref-type="bibr" rid="ref28">28</xref></p></sec><sec><title>Costs</title><p>In Canada, in accordance with the Canadian Health Care Act, all services considered as medically necessary are generally provided exclusively inside the public healthcare system and are free of charge. We considered only direct costs under the Ministry of Health and the Public Medical Assurance perspectives. Unit prices were averages for Quebec province calculated from government databases (financial and operative databank SIFO and APR-DRG). Costs for laboratory and imaging tests were from technical units for Quebec province.<xref ref-type="bibr" rid="ref29">29</xref> <xref ref-type="bibr" rid="ref30">30</xref> <xref ref-type="bibr" rid="ref31">31</xref> <xref ref-type="bibr" rid="ref32">32</xref> <xref ref-type="bibr" rid="ref33">33</xref> These unit prices include the costs of necessary support services (such as administration, security, cleaning, etc).<xref ref-type="bibr" rid="ref34">34</xref> Items considered for costing comprised screening costs and medical services related to the following outcomes&#x02014;birth, spontaneous miscarriage, elective abortion after positive test results, or pregnancy loss after a diagnostic test. Costs are expressed in Canadian dollars ($C) at 2007 values (exchange rate: $C1.0748=$US1.00).</p></sec><sec><title>Cost effectiveness analysis</title><p>Our approach follows guidelines for cost effectiveness analysis in prenatal diagnosis.<xref ref-type="bibr" rid="ref17">17</xref> The analyses were run to evaluate global costs, cost effectiveness ratios (costs per case of Down&#x02019;s syndrome diagnosed), and incremental cost effectiveness ratios comparing all 19 screening options. Incremental cost effectiveness ratio was calculated by dividing the difference in cost between each screening strategy and screening based on maternal age only (amniocentesis for women aged &#x02265;35 years) by the difference in the number of cases of Down&#x02019;s syndrome detected by the two strategies. The incremental cost effectiveness ratio therefore represents the additional cost or savings per additional abnormality detected. All measured costs occurred within one year; and so there was no need to discount costs and effects over time.<xref ref-type="bibr" rid="ref17">17</xref></p></sec><sec><title>Sensitivity analyses</title><p>In order to test the robustness of our findings, we performed a series of simulations (univariate sensitivity analyses) in which we varied the major assumptions of the modelling with values proposed in the AETMIS report<xref ref-type="bibr" rid="ref22">22</xref> and recalculated the cost effectiveness ratios.<xref ref-type="bibr" rid="ref17">17</xref> Apart from the values shown in tables 1<xref ref-type="table" rid="tbl1"/> and 2<xref ref-type="table" rid="tbl2"/>, we also tested the effects of </p><list list-type="bullet"><list-item><p>Rates of consent to participate in prenatal screening of 65% and 80%<xref ref-type="bibr" rid="ref22">22</xref></p></list-item><list-item><p>Rates of fetal loss from chorionic villous sampling of 0.5%, 1%, and 2%, and from amniocentesis of 1% and 1.5%<xref ref-type="bibr" rid="ref22">22</xref></p></list-item><list-item><p>The proportion of couples with a fetus with confirmed Down&#x02019;s syndrome who would undergo pregnancy termination, namely 70% and 80%</p></list-item><list-item><p>Varying the sensitivities and false positive rates of the screening strategies over the ranges achieved in the SURUSS trial.<xref ref-type="bibr" rid="ref9">9</xref> <xref ref-type="bibr" rid="ref13">13</xref></p></list-item></list></sec><sec><title>Estimation of confidence intervals</title><p>In order to generate 95% confidence intervals for our estimates of cost effectiveness ratios, we used the method of replications.<xref ref-type="bibr" rid="ref35">35</xref> This consisted of simulating each screening option 100 times on a virtual population of 110&#x02009;948 pregnancies (100&#x000d7;110&#x02009;948 individuals). It resulted in more than 11 million individuals being screened for computing the mean cost effectiveness ratios for each screening scenario.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Cost effectiveness analysis</title><p>Table 3<xref ref-type="table" rid="tbl3"/> summarises the results of our cost effectiveness analysis. The most cost effective screening strategy seems to be contingent screening (cost effectiveness ratio $C26&#x02009;833 per case of Down&#x02019;s syndrome with a high risk cut-off value of 1 in 30). These results were robust in sensitivity analyses: none of these different models yielded a different relative rank of the various screening scenarios analysed. Compared with the reference screening strategy (maternal age only), the incremental cost effectiveness ratio of contingent screening (with cut-off value of 1 in 6) is &#x02212;$C30&#x02009;963 per averted birth with Down&#x02019;s syndrome. The estimated costs per prevented birth with Down&#x02019;s syndrome were $C35&#x02009;215 for sequential screening, $C38&#x02009;944 for integrated screening, and $C43&#x02009;809 for the triple test. Consequently, the contingent screening strategy seems to be most cost effective. As expected, amniocentesis based on advanced maternal age only is the least cost effective option, with a cost effectiveness ratio of $C74&#x02009;037 per case of Down&#x02019;s syndrome.</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>&#x02002;Cost effectiveness analysis of different screening options in prenatal screening for Down&#x02019;s syndrome*</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="left" valign="bottom">Screening options</th><th colspan="1" rowspan="1" align="center" valign="bottom">Global costs ($Cmillions)&#x02020;</th><th colspan="1" rowspan="1" align="center" valign="bottom">Effectiveness&#x02021;</th><th colspan="1" rowspan="1" align="center" valign="bottom">Cost effectiveness ratio</th><th colspan="1" rowspan="1" align="center" valign="bottom">Incremental cost effectiveness ratio</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top">Amniocentesis for women &#x02265;35 years old</td><td colspan="1" rowspan="1" align="center" valign="top">4.1549</td><td colspan="1" rowspan="1" align="center" valign="top">56.12</td><td colspan="1" rowspan="1" align="center" valign="top">74 037</td><td colspan="1" rowspan="1" align="center" valign="top">1.00</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Contingent screening, cut-off values for first trimester test:</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/6</td><td colspan="1" rowspan="1" align="center" valign="top">2.7529</td><td colspan="1" rowspan="1" align="center" valign="top">101.40</td><td colspan="1" rowspan="1" align="center" valign="top">27 149</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;30 963</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/9</td><td colspan="1" rowspan="1" align="center" valign="top">2.7630</td><td colspan="1" rowspan="1" align="center" valign="top">102.48</td><td colspan="1" rowspan="1" align="center" valign="top">26 961</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;30 025</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/30</td><td colspan="1" rowspan="1" align="center" valign="top">2.8579</td><td colspan="1" rowspan="1" align="center" valign="top">106.51</td><td colspan="1" rowspan="1" align="center" valign="top">26 833</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;25 739</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/58</td><td colspan="1" rowspan="1" align="center" valign="top">2.9960</td><td colspan="1" rowspan="1" align="center" valign="top">108.67</td><td colspan="1" rowspan="1" align="center" valign="top">27 570</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;22 054</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/114</td><td colspan="1" rowspan="1" align="center" valign="top">3.2596</td><td colspan="1" rowspan="1" align="center" valign="top">109.72</td><td colspan="1" rowspan="1" align="center" valign="top">29 708</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;16 704</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/175</td><td colspan="1" rowspan="1" align="center" valign="top">3.5509</td><td colspan="1" rowspan="1" align="center" valign="top">111.69</td><td colspan="1" rowspan="1" align="center" valign="top">31 792</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;10 871</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/237</td><td colspan="1" rowspan="1" align="center" valign="top">3.8494</td><td colspan="1" rowspan="1" align="center" valign="top">111.61</td><td colspan="1" rowspan="1" align="center" valign="top">34 490</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;5 506</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/307</td><td colspan="1" rowspan="1" align="center" valign="top">4.1999</td><td colspan="1" rowspan="1" align="center" valign="top">112.72</td><td colspan="1" rowspan="1" align="center" valign="top">37 260</td><td colspan="1" rowspan="1" align="center" valign="top">795</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Sequential screening, cut-off values for first trimester test:</td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/6</td><td colspan="1" rowspan="1" align="center" valign="top">3.6265</td><td colspan="1" rowspan="1" align="center" valign="top">100.88</td><td colspan="1" rowspan="1" align="center" valign="top">35 949</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;11 805</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/9</td><td colspan="1" rowspan="1" align="center" valign="top">3.6400</td><td colspan="1" rowspan="1" align="center" valign="top">101.63</td><td colspan="1" rowspan="1" align="center" valign="top">35 816</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;11 315</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/30</td><td colspan="1" rowspan="1" align="center" valign="top">3.7440</td><td colspan="1" rowspan="1" align="center" valign="top">106.32</td><td colspan="1" rowspan="1" align="center" valign="top">35 215</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;8 185</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/58</td><td colspan="1" rowspan="1" align="center" valign="top">3.8662</td><td colspan="1" rowspan="1" align="center" valign="top">109.07</td><td colspan="1" rowspan="1" align="center" valign="top">35 447</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;5 453</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/114</td><td colspan="1" rowspan="1" align="center" valign="top">4.1326</td><td colspan="1" rowspan="1" align="center" valign="top">108.78</td><td colspan="1" rowspan="1" align="center" valign="top">37 991</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;423</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/175</td><td colspan="1" rowspan="1" align="center" valign="top">4.4416</td><td colspan="1" rowspan="1" align="center" valign="top">112.37</td><td colspan="1" rowspan="1" align="center" valign="top">39 526</td><td colspan="1" rowspan="1" align="center" valign="top">5 096</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/237</td><td colspan="1" rowspan="1" align="center" valign="top">4.7597</td><td colspan="1" rowspan="1" align="center" valign="top">110.62</td><td colspan="1" rowspan="1" align="center" valign="top">43 027</td><td colspan="1" rowspan="1" align="center" valign="top">11 096</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">&#x02003;1/307</td><td colspan="1" rowspan="1" align="center" valign="top">5.0960</td><td colspan="1" rowspan="1" align="center" valign="top">112.46</td><td colspan="1" rowspan="1" align="center" valign="top">45 314</td><td colspan="1" rowspan="1" align="center" valign="top">16 704</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Integrated test</td><td colspan="1" rowspan="1" align="center" valign="top">3.3944</td><td colspan="1" rowspan="1" align="center" valign="top">87.16</td><td colspan="1" rowspan="1" align="center" valign="top">38 944</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;24 502</td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top">Triple test</td><td colspan="1" rowspan="1" align="center" valign="top">3.8324</td><td colspan="1" rowspan="1" align="center" valign="top">87.48</td><td colspan="1" rowspan="1" align="center" valign="top">43 809</td><td colspan="1" rowspan="1" align="center" valign="top">&#x02212;10 285</td></tr></tbody></table><table-wrap-foot><p>*Values are per 100&#x000a0;000 pregnancies in prenatal care for an overall 90% detection of cases of Down&#x02019;s syndrome.</p><p>&#x02020;Canadian dollars ($C), exchange rate in 2007: $C1.0748=$US1.00.</p><p>&#x02021;No of cases of Down&#x02019;s syndrome detected by screening test.</p></table-wrap-foot></table-wrap></sec><sec><title>Screening strategies outcomes</title><p>Depending on the specific end points that are considered, different screening approaches may seem more appropriate. The most appropriate screening test for Down&#x02019;s syndrome should have the lowest false positive rate (to minimise the number of invasive procedures required and their related complications), the highest detection rate, and the best cost effectiveness ratio.<xref ref-type="bibr" rid="ref16">16</xref> The screening procedure (non-invasive screening and diagnostic technique) may also interfere with the number of live births with Down&#x02019;s syndrome. Figure 2<xref ref-type="fig" rid="fig2"/> shows the effects of the different screening strategies on these major end points&#x02014;false positive rate, number of procedure-related euploid miscarriages, and number of live births with Down&#x02019;s syndrome.</p><fig id="fig2" position="float"><caption><p><bold>Fig 2</bold>&#x02002;Effects of different prenatal screening strategies for Down&#x02019;s syndrome on (A) rate of false positive results, (B) number of procedure related euploid miscarriages, and (C) number of live births with Down&#x02019;s syndrome (all values are per 100&#x02009;000 pregnancies)</p></caption><graphic xlink:href="gekj586503.f2"/></fig><p>Early diagnosis of pregnancies affected by Down&#x02019;s syndrome may result in unnecessary terminations since some of the affected fetuses would be spontaneously aborted before term.<xref ref-type="bibr" rid="ref9">9</xref> Some studies have suggest that, in order to avoid this problem, women prefer a lower false positive rate,<xref ref-type="bibr" rid="ref36">36</xref> <xref ref-type="bibr" rid="ref37">37</xref> but others suggest that women want early diagnosis.<xref ref-type="bibr" rid="ref38">38</xref> <xref ref-type="bibr" rid="ref39">39</xref> We evaluated the effect of the different screening strategies on this issue by calculating the number of unnecessary terminations, the proportion of pregnancies affected by Down&#x02019;s syndrome screened by a first trimester test, and the proportion of continuing pregnancies that proceed to a second trimester test (fig 3<xref ref-type="fig" rid="fig3"/>).</p><fig id="fig3" position="float"><caption><p><bold>Fig 3</bold>&#x02002;Effects of different prenatal screening strategies for Down&#x02019;s syndrome on (A) number of unnecessary terminations, (B) proportion of pregnancies affected by Down&#x02019;s syndrome screened by a first trimester test, and (C) proportion of continuing pregnancies that proceed to a second trimester test (all values are per 100&#x02009;000 pregnancies)</p></caption><graphic xlink:href="gekj586503.f3"/></fig><p>Contingent and sequential screening strategies produced similar results on the major outcomes&#x02014;respectively, 1.43% and 1.55% for false positive results (fig 2<xref ref-type="fig" rid="fig2"/>), six procedure related euploid miscarriages each (fig 2<xref ref-type="fig" rid="fig2"/>), 16 unnecessary terminations each (fig 3<xref ref-type="fig" rid="fig3"/>), and 43.71% and 44.13% of affected pregnancies with a positive first trimester test (fig 3<xref ref-type="fig" rid="fig3"/>) (these results are those achieved with the most favourable cut-off value). However, contingent screening was unique in permitting 77.81% of patients to be reassured at the first trimester and 77.95% of women to avoid retesting in the second trimester (proportion of continuing pregnancies that proceed to a second trimester testing, fig 3<xref ref-type="fig" rid="fig3"/>). Indeed, contingent screening (whatever the cut-off value) allowed about 78% of women (77.75% to 78.51%) to be reassured with a negative screening result early in gestation, which was obviously not possible integrated, sequential, or triple test screening strategies.</p><p>In the same manner, we found that integrated screening was associated with a low number of procedure related euploid miscarriages (n=6, fig 2<xref ref-type="fig" rid="fig2"/>) and, in conjunction with the triple test, gave the best result for unnecessary terminations (n=6 for both, fig 3<xref ref-type="fig" rid="fig3"/>). Moreover, the integrated test&#x02019;s false positive rate is close to those achieved by sequential and contingent screening (1.82%, 1.43%, and 1.55% respectively, fig 2<xref ref-type="fig" rid="fig2"/>).</p></sec><sec><title>Impact of cut-off values in first trimester screening</title><p>We simulated the use of different cut-off values for the risk of a fetus having Down&#x02019;s syndrome in the first trimester tests of the contingent and sequential screening strategies. For both contingent and sequential screening, these had significant effects on </p><list list-type="bullet"><list-item><p>Cost effectiveness ratios (from $C26&#x02009;833 to $C37&#x02009;260 and from $C35&#x02009;215 to $C45&#x02009;314 per case of Down&#x02019;s syndrome respectively, table 3<xref ref-type="table" rid="tbl3"/>)</p></list-item><list-item><p>False positive rate (1.55% to 3.69% and 1.43% to 3.66%, fig 2<xref ref-type="fig" rid="fig2"/>)</p></list-item><list-item><p>Number of procedure related euploid miscarriages (6 to 46 and 6 to 45, fig 2<xref ref-type="fig" rid="fig2"/>)</p></list-item><list-item><p>Number of unnecessary terminations (16 to 26 and 16 to 25, fig 3<xref ref-type="fig" rid="fig3"/>) </p></list-item><list-item><p>Proportion of affected pregnancies with a positive result from the first trimester test (44.1% to 86.1% and 43.7% to 86.3%, fig 3<xref ref-type="fig" rid="fig3"/>).</p></list-item></list></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Limitations of study</title><p>Our results are based on mathematical modelling and not on prospective observational data. However, we used empirical data and true healthcare costs as input parameters for the simulations. Given geographical limitations, resource differences between regions, and the many possible screening strategies for Down&#x02019;s syndrome, it is unlikely that a large scale, comprehensive, prospective, clinical trial could be organised across North America. Our approach was useful in allowing 19 different strategies to be assessed and compared simultaneously.<xref ref-type="bibr" rid="ref18">18</xref> <xref ref-type="bibr" rid="ref40">40</xref> <xref ref-type="bibr" rid="ref41">41</xref> <xref ref-type="bibr" rid="ref42">42</xref></p><p>Our reported cost effectiveness ratios were based on Qu&#x000e9;bec province&#x02019;s healthcare system and costs. However, given the robustness of our findings observed in the sensitivity analyses (in which we varied the values of the major assumptions of the modelling), our conclusions are likely to be applicable to other jurisdictions. The demographic characteristics of the population we simulated are similar to those of other Western countries. In particular, the mean maternal age and the proportion of women aged &#x02265;35 years were similar to those of the populations of the SURUSS and the FASTER trials, which represented women in the UK and US.<xref ref-type="bibr" rid="ref12">12</xref> <xref ref-type="bibr" rid="ref13">13</xref> The effect of the maternal age distribution on the detection rate of Down&#x02019;s syndrome is reported to be limited and unlikely to be large enough to influence screening policy decisions.<xref ref-type="bibr" rid="ref43">43</xref> Also, pregnancy outcomes are likely to be similar across different populations. With respect to healthcare costs, they could be estimated for other provinces by using other costs units in the simulation model.</p><p>Most improvements in overall cost effectiveness attained with a screening strategy are due to the reduction in live births with Down&#x02019;s syndrome.<xref ref-type="bibr" rid="ref18">18</xref> An important drawback of studies that incorporate the future costs of caring for a child with Down&#x02019;s syndrome into their cost effectiveness or cost utility analyses<xref ref-type="bibr" rid="ref6">6</xref> <xref ref-type="bibr" rid="ref44">44</xref> is that they do not incorporate commensurate benefits of having such a child.<xref ref-type="bibr" rid="ref45">45</xref> In accordance with previous reports,<xref ref-type="bibr" rid="ref9">9</xref> <xref ref-type="bibr" rid="ref46">46</xref> <xref ref-type="bibr" rid="ref47">47</xref> <xref ref-type="bibr" rid="ref48">48</xref> we decided not to consider the cost of caring for a child with Down&#x02019;s syndrome. However, computing the cost per case of Down&#x02019;s syndrome detected allows us to compare different screening strategies on a common ground.</p><p>Our study did not consider the logistical problems and costs of implementing a screening strategy that includes nuchal translucency measurement or chorionic villous sampling in North America.<xref ref-type="bibr" rid="ref8">8</xref> <xref ref-type="bibr" rid="ref15">15</xref> Neither technique is universally available throughout the US and Canada,<xref ref-type="bibr" rid="ref15">15</xref> <xref ref-type="bibr" rid="ref18">18</xref> and the cost of establishing a screening programme with mandatory use of the techniques, including its administrative and technical challenges, is unknown.<xref ref-type="bibr" rid="ref15">15</xref> <xref ref-type="bibr" rid="ref50">50</xref> Because of this, some have speculated that such a screening programme is not justifiable<xref ref-type="bibr" rid="ref15">15</xref> or has serious implications for resource use.<xref ref-type="bibr" rid="ref16">16</xref> </p></sec><sec><title>Cut-off values for contingent and sequential screening options</title><p>There is no consensus on what are the most appropriate cut-off values for high risk in the first trimester tests for contingent and sequential screening strategies,<xref ref-type="bibr" rid="ref8">8</xref> even though they could have a major effect on screening performance.<xref ref-type="bibr" rid="ref6">6</xref> <xref ref-type="bibr" rid="ref9">9</xref> Our data show the impact of modulating the cut-off values and confirm that, for risk assessment to be successful, a careful choice of cut-off is required.</p><p>The first aim of using non-invasive screening is to reduce the number of procedure related euploid miscarriages.<xref ref-type="bibr" rid="ref50">50</xref> Our analysis suggests that first trimester cut-off values for high risk of 1 in 6 and 1 in 9 are most appropriate because they lead to the same number of procedure-related euploid miscarriages as occurs with the integrated test (which is considered the optimum screening option for limiting the procedure related euploid miscarriages<xref ref-type="bibr" rid="ref9">9</xref>). With these cut-off values, contingent screening remains more cost effective than the integrated test and sequential screening. Our results are consistent with those of Wald et al,<xref ref-type="bibr" rid="ref9">9</xref> who reported that, with a first trimester cut-off point for high risk of 1 in 30, the number of procedure-related euploid miscarriages was greater in contingent and sequential screening options than in the integrated test, and that contingent screening, but not sequential screening, was more cost effective than the integrated test.<xref ref-type="bibr" rid="ref9">9</xref></p><p>For contingent screening, the optimal cut-off value seems to be 1 in 9 cut-off with regard to cost effectiveness. The cut-off value of 1 in 30 showed the best cost effectiveness ratio, whereas the value of 1 in 6 produced the best incremental cost effectiveness ratio: hence, an in between value of 1 in 9 should achieve the best balance between these performance measures.</p><p>This value has important implications because the first trimester cut-off values traditionally used by healthcare professionals are much lower. Before the development of new screening strategies that combine first and second trimester tests,<xref ref-type="bibr" rid="ref7">7</xref> <xref ref-type="bibr" rid="ref8">8</xref> only the combined test (first trimester measurement of nuchal translucency, pregnancy associated plasma protein A, and &#x003b2; human chorionic gonadotrophin) used a first trimester cut-off value. The value for this test, which has become the de facto standard of care in the UK and may spread in North America,<xref ref-type="bibr" rid="ref6">6</xref> <xref ref-type="bibr" rid="ref51">51</xref> is 1 in 670 for obtaining a 90% detection rate.<xref ref-type="bibr" rid="ref13">13</xref> With strategies that combine first and second trimester tests,<xref ref-type="bibr" rid="ref7">7</xref> <xref ref-type="bibr" rid="ref8">8</xref> healthcare workers would have to be prepared (and trained) for the use of the much higher level of 1 in 9, and appropriate information would be needed for patients. Risk levels are often misunderstood by patients,<xref ref-type="bibr" rid="ref52">52</xref> and it may be difficult to refuse a diagnostic test at first trimester for an anxious woman with a calculated risk close to the 1 in 9 cut-off point because some women want an early diagnosis.<xref ref-type="bibr" rid="ref38">38</xref> <xref ref-type="bibr" rid="ref39">39</xref> However, the use of inappropriate cut-off values in the first trimester may produce an excess in iatrogenic losses and costs.</p></sec><sec><title>Different screening strategies</title><sec><title>Contingent screening</title><p>Our results confirm previous reports<xref ref-type="bibr" rid="ref6">6</xref> that contingent screening dominates all other options: </p><list list-type="bullet"><list-item><p>Best cost effectiveness for achieving a lower overall false positive rate leading to better outcomes</p></list-item><list-item><p>Fewer procedure related euploid miscarriages and unnecessary terminations</p></list-item><list-item><p>Lowest cost per case of Down&#x02019;s syndrome detected </p></list-item><list-item><p>Best incremental cost effectiveness ratio.</p></list-item></list><p>Contingent screening also offers early testing to those most likely to have an affected pregnancy (as does sequential screening), and it is the only option that allows the majority of women to be reassured early in gestation. Furthermore, it minimises costs by limiting retesting at the second trimester. Avoiding such repeat blood tests is a major reduction in unneeded clinic visits and their attendant costs. In our model, starting with 110&#x02009;948 pregnancies, the removal of about 86&#x02009;484 second clinic visits, blood draws, and reagent costs, results in major cost savings. Additionally, savings to the patients in terms of travel and time off work, are not to be ignored.<xref ref-type="bibr" rid="ref5">5</xref></p><p>It has been proposed that all women who screen negative at the first trimester will still require screening at the second trimester for neural tube defects<xref ref-type="bibr" rid="ref8">8</xref> and that this may affect the cost effectiveness of contingent screening.<xref ref-type="bibr" rid="ref9">9</xref> However, this is not applicable in our study since the standard practice in Canada and similar countries is that all women undergo a fetal ultrasound assessment at 20 weeks of gestation,<xref ref-type="bibr" rid="ref5">5</xref> <xref ref-type="bibr" rid="ref50">50</xref> so that a second trimester test for serum &#x003b1; fetoprotein seems to be unnecessary.<xref ref-type="bibr" rid="ref5">5</xref></p></sec><sec><title>Sequential screening</title><p>In accordance with reported data,<xref ref-type="bibr" rid="ref6">6</xref> <xref ref-type="bibr" rid="ref9">9</xref> we found sequential screening to be outperformed by contingent screening. This is probably due to the high proportion of women who proceed to a second trimester test under the sequential screening scenario. However, the contingent and sequential screening options are very similar with regard to other outcomes.</p></sec><sec><title>Integrated test</title><p>Our results confirm reports that the integrated test results in few procedure related euploid miscarriages<xref ref-type="bibr" rid="ref9">9</xref> and that its principal advantage is the low number of unnecessary terminations (because this screening option allows a diagnostic test only in the second trimester). However, the integrated test does not allow identification of affected pregnancies at the first trimester, nor reassurance for women with unaffected pregnancies. This could be a disadvantage given that women seem to want an early diagnosis.<xref ref-type="bibr" rid="ref38">38</xref> <xref ref-type="bibr" rid="ref39">39</xref></p></sec><sec><title>Triple test</title><p>Considering cost effectiveness and outcomes, triple test has too many limitations to be maintained as a desirable Down&#x02019;s syndrome screening strategy. But a screening option that starts in second trimester should also be available because one third of women seek prenatal care after the first trimester.<xref ref-type="bibr" rid="ref7">7</xref></p></sec><sec><title>Amniocentesis for women aged &#x02265;35 years</title><p>We show here that scheduling an amniocentesis for women aged &#x02265;35 years is not a cost effective strategy and should be abandoned rapidly. Also, this approach may produce seven times more procedure related euploid miscarriages than contingent screening. </p></sec></sec><sec><title>What screening option?</title><p>We conclude that, depending on local conditions,<xref ref-type="bibr" rid="ref16">16</xref> contingent screening is the preferred screening strategy for Down&#x02019;s syndrome with a first trimester cut-off value for risk of 1 in 9. Obviously, if it becomes possible to perform non-invasive prenatal diagnosis of Down&#x02019;s syndrome by means of fetal DNA or cells in maternal blood new cost effectiveness studies will be needed.<xref ref-type="bibr" rid="ref12">12</xref> <xref ref-type="bibr" rid="ref53">53</xref> <xref ref-type="bibr" rid="ref54">54</xref> </p><boxed-text position="float" content-type="style3"><sec><title>What is already known on this topic</title><list list-type="bullet"><list-item><p>Prenatal screening for Down&#x02019;s syndrome is widely used, with many different screening strategies but still no consensus on the most cost effective approach</p></list-item><list-item><p>New strategies that provide a relatively high detection rate combine tests at both first and second trimesters</p></list-item></list></sec><sec><title>What this study adds</title><list list-type="bullet"><list-item><p>For strategies that combine first and second trimester tests, the choice of cut-off value for risk in the first trimester test significantly influences the cost effectiveness ratios and outcomes</p></list-item><list-item><p>Contingent screening, with a first trimester cut-off value for high risk of 1 in 9, is the preferred option. This cut-off value is much higher than those generally used in screening programmes</p></list-item></list></sec></boxed-text></sec></sec></body><back><notes><fn-group><fn fn-type="participating-researchers"><p>Contributors: JG was principal investigator and was responsible for the study design and coordination, analysis of data, and drafting the manuscript. DR, GG, and DD made the computer simulations of screening procedures and contributed to the data analysis and drafting the manuscript. EB validated the clinical design of the study and contributed to drafting the manuscript. JF and FR were responsible for analysis of pregnancies&#x02019; characteristics and screening options applicable in Qu&#x000e9;bec and interpretation of results and contributed to drafting the manuscript. JG is the guarantor for the study.</p></fn><fn fn-type="financial-disclosure"><p>Funding: This study was funded by the CanG&#x000e8;neTest research consortium on genetic laboratory services through a team grant from the Institute of Genetics of the Canadian Institutes for Health Research, the Heart and Stroke Foundation of Canada, the Canadian Agency for Drugs and Technologies in Health, and the Canadian Genetics Diseases Network of Centres of Excellence. EB holds a clinician-scientist award from the Canadian Institute for Health Research and the Jeanne et Jean-Louis L&#x000e9;vesque Perinatal Research Chair at Laval University.</p></fn><fn fn-type="conflict"><p>Competing interests: None declared.</p></fn></fn-group></notes><ref-list><ref id="ref1"><label>1</label><citation citation-type="journal">Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down&#x02019;s syndrome on the basis of tests performed during the first and second trimesters. <source>N Engl J Med</source><year>1999</year>;<volume>341</volume>:<fpage>461</fpage>-7.<pub-id pub-id-type="pmid">10441601</pub-id></citation></ref><ref id="ref2"><label>2</label><citation citation-type="journal">Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al. First-trimester screening for trisomies 21 and 18. <source>N Engl J Med</source><year>2003</year>;<volume>349</volume>:<fpage>1405</fpage>-13.<pub-id pub-id-type="pmid">14534333</pub-id></citation></ref><ref id="ref3"><label>3</label><citation citation-type="journal">Roizen NJ, Patterson D. Down&#x02019;s syndrome. <source>Lancet</source><year>2003</year>;<volume>361</volume>:<fpage>1281</fpage>-9.<pub-id pub-id-type="pmid">12699967</pub-id></citation></ref><ref id="ref4"><label>4</label><citation citation-type="journal">Resta RG. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: implications for prenatal screening and genetic counseling. <source>Am J Med Genet A</source><year>2005</year>;<volume>133</volume>:<fpage>31</fpage>-6.</citation></ref><ref id="ref5"><label>5</label><citation citation-type="journal">Wyatt P. Integrated, sequential, and contingent screening for Down syndrome&#x02014;local needs should drive methodology. <source>Prenat Diagn</source><year>2007</year>;<volume>27</volume>:<fpage>186</fpage>-7.<pub-id pub-id-type="pmid">17266162</pub-id></citation></ref><ref id="ref6"><label>6</label><citation citation-type="journal">Ball RH, Caughey AB, Malone FD, Nyberg DA, Comstock CH, Saade GR, et al. First- and second-trimester evaluation of risk for Down syndrome. <source>Obstet Gynecol</source><year>2007</year>;<volume>110</volume>:<fpage>10</fpage>-7.<pub-id pub-id-type="pmid">17601890</pub-id></citation></ref><ref id="ref7"><label>7</label><citation citation-type="journal">Reddy UM, Wapner RJ. Comparison of first and second trimester aneuploidy risk assessment. <source>Clin Obstet Gynecol</source><year>2007</year>;<volume>50</volume>:<fpage>442</fpage>-53.<pub-id pub-id-type="pmid">17513930</pub-id></citation></ref><ref id="ref8"><label>8</label><citation citation-type="journal">Reddy UM. The evolving prenatal screening scene. <source>Obstet Gynecol</source><year>2007</year>;<volume>110</volume>:<fpage>2</fpage>-4.<pub-id pub-id-type="pmid">17601887</pub-id></citation></ref><ref id="ref9"><label>9</label><citation citation-type="journal">Wald NJ, Rudnicka AR, Bestwick JP. Sequential and contingent prenatal screening for Down syndrome. <source>Prenat Diagn</source><year>2006</year>;<volume>26</volume>:<fpage>769</fpage>-77.<pub-id pub-id-type="pmid">16821246</pub-id></citation></ref><ref id="ref10"><label>10</label><citation citation-type="journal">Platt LD, Greene N, Johnson A, Zachary J, Thom E, Krantz D, et al. Sequential pathways of testing after first-trimester screening for trisomy 21. <source>Obstet Gynecol</source><year>2004</year>;<volume>104</volume>:<fpage>661</fpage>-6.<pub-id pub-id-type="pmid">15458882</pub-id></citation></ref><ref id="ref11"><label>11</label><citation citation-type="journal">Benn P, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. <source>Prenat Diagn</source><year>2005</year>;<volume>25</volume>:<fpage>645</fpage>-52.<pub-id pub-id-type="pmid">16049988</pub-id></citation></ref><ref id="ref12"><label>12</label><citation citation-type="journal">Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down&#x02019;s syndrome. <source>N Engl J Med</source><year>2005</year>;<volume>353</volume>:<fpage>2001</fpage>-11.<pub-id pub-id-type="pmid">16282175</pub-id></citation></ref><ref id="ref13"><label>13</label><citation citation-type="journal">Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down&#x02019;s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). <source>J Med Screen</source><year>2003</year>;<volume>10</volume>:<fpage>56</fpage>-104.<pub-id pub-id-type="pmid">14746340</pub-id></citation></ref><ref id="ref14"><label>14</label><citation citation-type="journal">Palomaki GE, Steinort K, Knight GJ, Haddow JE. Comparing three screening strategies for combining first- and second-trimester Down syndrome markers. <source>Obstet Gynecol</source><year>2006</year>;<volume>107</volume>(2 Pt 1):<fpage>367</fpage>-75.<pub-id pub-id-type="pmid">16449126</pub-id></citation></ref><ref id="ref15"><label>15</label><citation citation-type="journal">Kotaska A. Prenatal screening for fetal aneuploidy. <source>J Obstet Gynaecol Can</source><year>2007</year>;<volume>29</volume>:<fpage>499</fpage>-500.<pub-id pub-id-type="pmid">17568480</pub-id></citation></ref><ref id="ref16"><label>16</label><citation citation-type="journal">Summers AM, Langlois S, Wyatt P, Wilson RD. Prenatal screening for fetal aneuploidy. <source>J Obstet Gynaecol Can</source><year>2007</year>;<volume>29</volume>:<fpage>146</fpage>-79.<pub-id pub-id-type="pmid">17346485</pub-id></citation></ref><ref id="ref17"><label>17</label><citation citation-type="journal">Caughey AB. Cost-effectiveness analysis of prenatal diagnosis: methodological issues and concerns. <source>Gynecol Obstet Invest</source><year>2005</year>;<volume>60</volume>:<fpage>11</fpage>-8.<pub-id pub-id-type="pmid">15692215</pub-id></citation></ref><ref id="ref18"><label>18</label><citation citation-type="journal">Biggio JR Jr, Morris TC, Owen J, Stringer JS. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. <source>Am J Obstet Gynecol</source><year>2004</year>;<volume>190</volume>:<fpage>721</fpage>-9.<pub-id pub-id-type="pmid">15042005</pub-id></citation></ref><ref id="ref19"><label>19</label><citation citation-type="journal">Boulware LE. Challenges for public campaigns to improve the health of persons at high risk of developing CKD. <source>Am J Kidney Dis</source><year>2008</year>;<volume>51</volume>:<fpage>535</fpage>-8.<pub-id pub-id-type="pmid">18371526</pub-id></citation></ref><ref id="ref20"><label>20</label><citation citation-type="other">Antenatal diagnosis. Report of a consensus development conference. Bethesda, MD: National Institutes of Health, 1979. (NIH Publication No 79-1973.)</citation></ref><ref id="ref21"><label>21</label><citation citation-type="other">Haute Autorit&#x000e9; de Sant&#x000e9;. &#x000c9;valuation des strat&#x000e9;gies de d&#x000e9;pistage de la trisomie 21. Recommandation en sant&#x000e9; publique Juin 2007.<ext-link ext-link-type="uri" xlink:href="http://www.has-sante.fr/portail/upload/docs/application/pdf/synthese_evaluation_des_strategies_de_depistage_de_la_trisomie_21.pdf">www.has-sante.fr/portail/upload/docs/application/pdf/synthese_evaluation_des_strategies_de_depistage_de_la_trisomie_21.pdf</ext-link></citation></ref><ref id="ref22"><label>22</label><citation citation-type="other">AETMIS. Le d&#x000e9;pistage pr&#x000e9;natal du syndrome de Down et d&#x02019;autres aneuplo&#x000ec;des au premier trimestre de la grossesse. 2003. (AETMIS 03-01) xxi:84. <ext-link ext-link-type="uri" xlink:href="http://www.aetmis.gouv.qc.ca/site/416.262.0.0.1.0.phtml">www.aetmis.gouv.qc.ca/site/416.262.0.0.1.0.phtml</ext-link></citation></ref><ref id="ref23"><label>23</label><citation citation-type="other">MSSS. Recensement de 2001. Institut de la Statistique du Qu&#x000e9;bec, 2007. <ext-link ext-link-type="uri" xlink:href="http://www.stat.gouv.qc.ca">www.stat.gouv.qc.ca</ext-link></citation></ref><ref id="ref24"><label>24</label><citation citation-type="journal">Morris JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down&#x02019;s syndrome. <source>J Med Screen</source><year>2002</year>;<volume>9</volume>:<fpage>2</fpage>-6.<pub-id pub-id-type="pmid">11943789</pub-id></citation></ref><ref id="ref25"><label>25</label><citation citation-type="journal">Morris J, Mutton D, Alberman E. Corrections to maternal age-specific live birth prevalence of Down&#x02019;s syndrome. <source>J Med Screen</source><year>2005</year>;<volume>12</volume>:<fpage>202</fpage><pub-id pub-id-type="pmid">16417698</pub-id></citation></ref><ref id="ref26"><label>26</label><citation citation-type="journal">Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. <source>Ultrasound Obstet Gynecol</source><year>1999</year>;<volume>13</volume>:<fpage>167</fpage>-70.<pub-id pub-id-type="pmid">10204206</pub-id></citation></ref><ref id="ref27"><label>27</label><citation citation-type="journal">Snijders R. Fetal loss in Down syndrome pregnancies. <source>Prenat Diagn</source><year>1999</year>;<volume>19</volume>:<fpage>1180</fpage><pub-id pub-id-type="pmid">10590443</pub-id></citation></ref><ref id="ref28"><label>28</label><citation citation-type="other">Forest J-C, Blouin D, Cartier L, D&#x000e9;silets V, Framarin A, Lemyre E, et al. <source>Rapport du comit&#x000e9; d&#x02019;experts sur le d&#x000e9;pistage pr&#x000e9;natal du syndrome de Down et autres aneuplo&#x000ee;dies</source> Qu&#x000e9;bec: CHUQ-CHUL, A&#x000c9;TMIS, MSSS, CHUS, CUSM, <year>2004</year></citation></ref><ref id="ref29"><label>29</label><citation citation-type="other">MSSS. Banque de donn&#x000e9;es APR-DRG (All Patient Refined Diagnosis Related Groups): Minist&#x000e8;re de la Sant&#x000e9; et des Services Sociaux du Qu&#x000e9;bec, 2003.</citation></ref><ref id="ref30"><label>30</label><citation citation-type="other">MSSS. <source>SIFO Syst&#x000e8;me d&#x02019;Information Financi&#x000e8;re et Op&#x000e9;rationnelle: m&#x000e9;thodologie</source> Quebec: Direction de la gestion de l&#x02019;information, Minist&#x000e8;re de la Sant&#x000e9; et des Services Sociaux (MSSS), <year>2005</year></citation></ref><ref id="ref31"><label>31</label><citation citation-type="other">MSSS. <source>Laboratoire de biologie m&#x000e9;dicale, Mesure de la production Edition 2006-2007</source> Quebec: La Direction des communications, Minist&#x000e8;re de la Sant&#x000e9; et des Services Sociaux (MSSS), <year>2007</year></citation></ref><ref id="ref32"><label>32</label><citation citation-type="other">RAMQ. Manuel des m&#x000e9;decins sp&#x000e9;cialistes. Quebec: R&#x000e9;gie de l&#x02019;assurance maladie du Qu&#x000e9;bec (RAMQ), Direction des services &#x000e0; la client&#x000e8;le professionnelle, 2005:607.</citation></ref><ref id="ref33"><label>33</label><citation citation-type="other">RAMQ. Manuel des m&#x000e9;decins sp&#x000e9;cialistes de laboratoires en &#x000e9;tablissement. Quebec: R&#x000e9;gie de l&#x02019;assurance maladie du Qu&#x000e9;bec (RAMQ), Direction des services &#x000e0; la client&#x000e8;le professionnelle, 2007:176.</citation></ref><ref id="ref34"><label>34</label><citation citation-type="other">Drummond MF, Sculpher MJ, Torrance GW, O&#x02019;Brien BJ, Stoddart GL. <source>Methods for the economic evaluation of health care programmes</source> 3rd ed. Oxford: Oxford University Press, <year>2005</year>:1-396.</citation></ref><ref id="ref35"><label>35</label><citation citation-type="other">Hoover SV, Perry RF. <source>Simulation: a problem-solving approach</source> London: Addison Wesley, <year>1989</year></citation></ref><ref id="ref36"><label>36</label><citation citation-type="journal">Bishop AJ, Marteau TM, Armstrong D, Chitty LS, Longworth L, Buxton MJ, et al. Women and health care professionals&#x02019; preferences for Down&#x02019;s syndrome screening tests: a conjoint analysis study. <source>BJOG</source><year>2004</year>;<volume>111</volume>:<fpage>775</fpage>-9.<pub-id pub-id-type="pmid">15270923</pub-id></citation></ref><ref id="ref37"><label>37</label><citation citation-type="journal">Carroll JC, Reid AJ, Woodward CA, Permaul-Woods JA, Domb S, Ryan G, et al. Ontario Maternal Serum Screening Program: practices, knowledge and opinions of health care providers. <source>CMAJ</source><year>1997</year>;<volume>156</volume>:<fpage>775</fpage>-84.<pub-id pub-id-type="pmid">9084382</pub-id></citation></ref><ref id="ref38"><label>38</label><citation citation-type="journal">Mulvey S, Zachariah R, McIlwaine K, Wallace EM. Do women prefer to have screening tests for Down syndrome that have the lowest screen-positive rate or the highest detection rate? <source>Prenat Diagn</source><year>2003</year>;<volume>23</volume>:<fpage>828</fpage>-32.<pub-id pub-id-type="pmid">14558028</pub-id></citation></ref><ref id="ref39"><label>39</label><citation citation-type="journal">Spencer K, Aitken D. Factors affecting women&#x02019;s preference for type of prenatal screening test for chromosomal anomalies. <source>Ultrasound Obstet Gynecol</source><year>2004</year>;<volume>24</volume>:<fpage>735</fpage>-9.<pub-id pub-id-type="pmid">15505874</pub-id></citation></ref><ref id="ref40"><label>40</label><citation citation-type="journal">Asch A. Prenatal diagnosis and selective abortion: a challenge to practice and policy. <source>Am J Public Health</source><year>1999</year>;<volume>89</volume>:<fpage>1649</fpage>-57.<pub-id pub-id-type="pmid">10553384</pub-id></citation></ref><ref id="ref41"><label>41</label><citation citation-type="journal">Kuppermann M, Feeny D, Gates E, Posner SF, Blumberg B, Washington AE. Preferences of women facing a prenatal diagnostic choice: long-term outcomes matter most. <source>Prenat Diagn</source><year>1999</year>;<volume>19</volume>:<fpage>711</fpage>-6.<pub-id pub-id-type="pmid">10451513</pub-id></citation></ref><ref id="ref42"><label>42</label><citation citation-type="journal">Kuppermann M, Goldberg JD, Nease RF Jr, Washington AE. Who should be offered prenatal diagnosis? The 35-year-old question. <source>Am J Public Health</source><year>1999</year>;<volume>89</volume>:<fpage>160</fpage>-3.<pub-id pub-id-type="pmid">9949742</pub-id></citation></ref><ref id="ref43"><label>43</label><citation citation-type="journal">Cuckle HS. Effect of maternal age curve on the predicted detection rate in maternal serum screening for Down syndrome. <source>Prenat Diagn</source><year>1998</year>;<volume>18</volume>:<fpage>1127</fpage>-30.<pub-id pub-id-type="pmid">9854719</pub-id></citation></ref><ref id="ref44"><label>44</label><citation citation-type="journal">Harris RA, Washington AE, Nease RF Jr, Kuppermann M. Cost utility of prenatal diagnosis and the risk-based threshold. <source>Lancet</source><year>2004</year>;<volume>363</volume>:<fpage>276</fpage>-82.<pub-id pub-id-type="pmid">14751700</pub-id></citation></ref><ref id="ref45"><label>45</label><citation citation-type="journal">Petrou S, Mugford M. Should prenatal diagnostic testing be offered to all pregnant women on economic grounds? <source>Lancet</source><year>2004</year>;<volume>363</volume>:<fpage>258</fpage>-9.<pub-id pub-id-type="pmid">14751693</pub-id></citation></ref><ref id="ref46"><label>46</label><citation citation-type="journal">Caughey AB, Kuppermann M, Norton ME, Washington AE. Nuchal translucency and first trimester biochemical markers for down syndrome screening: a cost-effectiveness analysis. <source>Am J Obstet Gynecol</source><year>2002</year>;<volume>187</volume>:<fpage>1239</fpage>-45.<pub-id pub-id-type="pmid">12439512</pub-id></citation></ref><ref id="ref47"><label>47</label><citation citation-type="journal">Chen Y, Qian X, Li J, Zhang J, Chu A, Schweitzer SO. Cost-effectiveness analysis of prenatal diagnosis intervention for Down&#x02019;s syndrome in China. <source>Int J Technol Assess Health Care</source><year>2007</year>;<volume>23</volume>:<fpage>138</fpage>-45.<pub-id pub-id-type="pmid">17234028</pub-id></citation></ref><ref id="ref48"><label>48</label><citation citation-type="journal">Ritchie K, Bradbury I, Slattery J, Wright D, Iqbal K, Penney G. Economic modelling of antenatal screening and ultrasound scanning programmes for identification of fetal abnormalities. <source>BJOG</source><year>2005</year>;<volume>112</volume>:<fpage>866</fpage>-74.<pub-id pub-id-type="pmid">15957985</pub-id></citation></ref><ref id="ref49"><label>49</label><citation citation-type="journal">Egan JF, Kaminsky LM, DeRoche ME, Barsoom MJ, Borgida AF, Benn PA. Antenatal Down syndrome screening in the United States in 2001: a survey of maternal-fetal medicine specialists. <source>Am J Obstet Gynecol</source><year>2002</year>;<volume>187</volume>:<fpage>1230</fpage>-4.<pub-id pub-id-type="pmid">12439510</pub-id></citation></ref><ref id="ref50"><label>50</label><citation citation-type="other">Scott A. Nuchal translucency measurement in first trimester Down syndrome screening. <source>Issues Emerg Health Technol</source><year>2007</year>;(100):1-6.</citation></ref><ref id="ref51"><label>51</label><citation citation-type="journal">American College of Obstetricians and Gynecologists. First-trimester screening for fetal aneuploidy: opinion 296. <source>Obstet Gynecol</source><year>2004</year>;<volume>104</volume>:<fpage>215</fpage>-7.<pub-id pub-id-type="pmid">15229041</pub-id></citation></ref><ref id="ref52"><label>52</label><citation citation-type="journal">Gekas J, Gondry J, Mazur S, Cesbron P, Thepot F. Informed consent to serum screening for Down syndrome: are women given adequate information? <source>Prenat Diagn</source><year>1999</year>;<volume>19</volume>:<fpage>1</fpage>-7.<pub-id pub-id-type="pmid">10073897</pub-id></citation></ref><ref id="ref53"><label>53</label><citation citation-type="journal">Lau TK, Leung TN. Genetic screening and diagnosis. <source>Curr Opin Obstet Gynecol</source><year>2005</year>;<volume>17</volume>:<fpage>163</fpage>-9.<pub-id pub-id-type="pmid">15758610</pub-id></citation></ref><ref id="ref54"><label>54</label><citation citation-type="journal">Jackson L. Fetal cells and DNA in maternal blood. <source>Prenat Diagn</source><year>2003</year>;<volume>23</volume>:<fpage>837</fpage>-46.<pub-id pub-id-type="pmid">14558030</pub-id></citation></ref><ref id="ref55"><label>55</label><citation citation-type="journal">Morris JK, Wald NJ, Watt HC. Fetal loss in Down syndrome pregnancies. <source>Prenat Diagn</source><year>1999</year>;<volume>19</volume>:<fpage>142</fpage>-5.<pub-id pub-id-type="pmid">10215072</pub-id></citation></ref><ref id="ref56"><label>56</label><citation citation-type="journal">Sundberg K, Bang J, Smidt-Jensen S, Brocks V, Lundsteen C, Parner J, et al. Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. <source>Lancet</source><year>1997</year>;<volume>350</volume>:<fpage>697</fpage>-703.<pub-id pub-id-type="pmid">9291904</pub-id></citation></ref><ref id="ref57"><label>57</label><citation citation-type="other">CETS. Les enjeux du d&#x000e9;pistage et du diagnostic pr&#x000e9;natals du syndrome de Down. 1999;(CETS 99-4 RF) xviii:92.</citation></ref></ref-list><notes notes-type="citation-text"><p><bold>Cite this as:</bold> <italic>BMJ</italic> 2009;338:b138</p></notes></back></article>